NEW YORK, Nov. 26, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the Board of Directors of The Medicines
Co. ("MDCO" or the "Company") (NASDAQ: MDCO) in connection with the
proposed acquisition of the Company by Swiss pharmaceutical company
Novartis International A.G. Under the terms of the acquisition
agreement, MDCO shareholders will receive $85.00 for each share they own.
If you own MDCO shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website:
http://www.weisslawllp.com/the-medicines-co/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether MDCO's Board acted to maximize
shareholder value prior to entering into the acquisition
agreement. Notably, at least one analyst set a target price
of $95.00 per MDCO share, or
$10.00 above the offer price.
Additionally, prior to the acquisition announcement, MDCO
announced promising results from Phase 3 of the clinical studies of
Inclisiran, the Company's investigational therapy for the treatment
of LDL cholesterol. MDCO reported that the drug met "all
primary and secondary efficacy endpoints, was well-tolerated and
demonstrated an excellent safety profile."
Given these facts, WeissLaw is concerned whether the proposed
acquisition undervalues the Company, and whether all material
information related to the proposed acquisition is fully and fairly
disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-the-medicines-co-300965752.html
SOURCE WeissLaw LLP